BIOTERRORBIBLE.COM: There is an ever expanding list of potential bio-terror agents that could be used in a bio-terror attack, but anthraxsmallpox and flu are the only “threats” the government appears worried about. These 3 agents will likely be used the same way that they were used in the U.S. government bio-terror war-games entitled Dark Winter and Atlantic Storm

Title: West Nile Virus

Abstract: West Nile virus (WNV) is a virus of the family Flaviviridae. Part of the Japanese encephalitis (JE) antigenic complex of viruses, it is found in both tropical and temperate regions. It mainly infects birds, but is known to infect humans, horses, dogs, cats, bats, chipmunks, skunks, squirrels, domestic rabbits, crows, robins, crocodiles and alligators. The main route of human infection is through the bite of an infected mosquito. Approximately 90% of West Nile Virus infections in humans are without any symptoms.

Image reconstructions and cryoelectron microscopy reveal a 45–50 nm virion covered with a relatively smooth protein surface. This structure is similar to the dengue fever virus; both belong to the genus Flavivirus within the family Flaviviridae. The genetic material of WNV is a positive-sense, single strand of RNA, which is between 11,000 and 12,000 nucleotides long; these genes encode seven non-structural proteins and three structural proteins. The RNA strand is held within a nucleocapsid formed from 12 kDa protein blocks; the capsid is contained within a host-derived membrane altered by two viral glycoproteins.

The West Nile Virus produces one of three different outcomes in humans. The first is an asymptomatic infection; the second is a mild febrile syndrome termed West Nile Fever; the third is a neuroinvasive disease termed West Nile meningitis or encephalitis. The population proportion of these three states is roughly 110:30:1.

The second, febrile stage has an incubation period of 2 to 8 days followed by fever, headache, chills, diaphoresis (excessive sweating), weakness, lymphadenopathy (swollen lymph nodes), drowsiness, pain in the joints and symptoms like those of influenza or the flu. Occasionally there is a short-lived truncal rash and some patients experience gastrointestinal symptoms including nausea, vomiting, loss of appetite, or diarrhea. Symptoms are generally resolved within 7 to 10 days, although fatigue can persist for some weeks and lymphadenopathy up to two months.

The more dangerous encephalitis is characterized by similar early symptoms but also a decreased level of consciousness, sometimes approaching near-coma. Deep tendon reflexes are hyperactive at first, later diminished. There are also extrapyramidal disorders. Recovery is marked by a long convalescence with fatigue.

More recent outbreaks have resulted in a deeper study of the disease and other, rarer, outcomes have been identified. The spinal cord may be infected, marked by anterior myelitis with or without encephalitis. WNV-associated Guillain-Barré syndrome has been identified and other rare effects include multifocal chorioretinitis (which has 100% specificity for identifying WNV infection in patients with possible WNV encephalitis), hepatitis, myocarditis, nephritis, pancreatitis, and splenomegaly.

Mortality Rate
There is no way to accurately measure the number of worldwide cases at this time. However, the United States keeps records of West Nile infection cases. In 2009, there were 663 cases. Three hundred and thirty-five of these cases were encephalitis or meningitis infections, a reaction to the virus that approximately 1 in 150 people who get the virus will show. Three hundred two cases were filed for West Nile fever, the most likely symptom of the virus. Twenty six cases were unspecified. The state of Texas had the most cases, with 104 total. The total mortality rate for 2009 was 30 deaths of the 663 reported serious cases. That is a 4.5% casualty rate, but only of the severe infections. Approximately 80% of cases have no symptoms, and therefore the total casualty rate would be less than 1% of total infections in the U.S. This data and earlier years data is available from the
Centers for Disease Control and Prevention (CDC).

Transmission & Susceptibility

The proboscis of an Aedes albopictus mosquito feeding on human blood. Under experimental conditions, the Aedes albopictus mosquito (also known as the Asian Tiger Mosquito) has been found to be a vector of West Nile Virus.

The virus is transmitted through mosquito vectors, which bite and infect birds. The birds are amplifying hosts, developing sufficient viral levels to transmit the infection to other biting mosquitoes which go on to infect other birds (in the Western hemisphere the American robin and the American crow are the most common carriers) and also humans. The infected mosquito species vary according to geographical area; in the US Culex pipiens (Eastern US), Culex tarsalis (Midwest and West), and Culex quinquefasciatus (Southeast) are the main sources.

In mammals the virus does not multiply as readily (i.e. does not develop high viremia during infection), and it is believed that mosquitoes biting infected mammals do not ingest sufficient virus to become infected, making mammals so-called dead-end infections.

A 2004 paper in Science found that Culex pipiens mosquitoes existed in two populations in Europe, one which bites birds and one which bites humans. In North America 40% of Culex pipiens were found to be hybrids of the two types which bite both birds and humans, providing a vector for WNV. This is argued to provide an explanation of why the West Nile disease has spread more quickly in North America than Europe. However, these conclusions have been disputed. In 2010 it was verified by the Greek Center for Disease Control and Prevention that Culex pipiens was responsible for an outbreak of the virus in northern Greece.

It was initially believed that direct human-to-human transmission was only caused by occupational exposure, or conjunctival exposure to infected blood. The US outbreak revealed novel transmission methods, through blood transfusion, organ transplant, intrauterine exposure, and breast feeding. Since 2003, blood banks in the US routinely screen for the virus amongst their donors. As a precautionary measure, the UK's National Blood Service initially ran a test for this disease in donors who donate within 28 days of a visit to the United States, Canada or the North Eastern provinces of Italy. Currently (September 2011) the policy of the National Blood Service is as follows:

"In the last year there have been significant outbreaks in mainland Greece, Romania, Albania, Israel and in the south west of the Russian Federation just north of the Black and Caspian seas. In recent years North Eastern Italy in the provincial districts of Ferrara, Rovigo, Mantua, Modena, Bologna and Reggio Emilia (an area north of Rimini and east of Parma) have also been affected. Donors who have visited a WNV endemic area between April 1st and November 30th may donate blood four weeks after their return, as long as they have had neither symptoms nor evidence of infection. If the donor was diagnosed with WNV, or had a history of symptoms suggestive of WNV, whilst in the endemic area or following their return then they must wait 6 months before donating."

The Scottish National Blood Transfusion Service is to ask prospective donors to wait 28 days after returning from North America or the North Eastern provinces of Italy before donating.

The more severe outcomes of WNV infection are clearly associated with advancing age and a patient history of organ transplantation and diabetes. A genetic factor also appears to increase susceptibility to West Nile disease. A mutation of the gene CCR5 gives some protection against HIV but leads to more serious complications of WNV infection. Carriers of two mutated copies of CCR5 made up 4 to 4.5% of a sample of West Nile disease sufferers while the incidence of the gene in the general population is only 1%.

Recently, the potential for mosquito saliva to impact the course of WNV disease was demonstrated. Mosquitoes inoculate their saliva into the skin while obtaining blood. Mosquito saliva is a pharmacologic cocktail of secreted molecules, principally proteins, that can affect vascular constriction, blood coagulation, platelet aggregation, inflammation, and immunity. It has become clear that mosquito saliva alters the immune response in a manner that may be advantageous to a virus. Studies have shown that it can specifically modulate the immune response during early virus infection, and mosquito feeding can exacerbate WNV infection leading to higher viremia and more severe forms of disease. It is unknown what benefit, if any, the mosquito receives by assisting the virus in this manner, so it is likely that the virus is simply exploiting the preexisting qualities of mosquito saliva developed for other purposes.

There is no vaccine for humans. A vaccine for horses (ATCvet code: QI05AA10) based on killed viruses exists; some zoos have given this vaccine to their birds, although its effectiveness there is unknown. Dogs and cats show few if any signs of infection. There have been no known cases of direct canine-human or feline-human transmission; although these pets can become infected, it is unlikely that they are in turn capable of infecting native mosquitoes and thus continuing the disease cycle.

Avoiding mosquito bites is the most straightforward means to avoid infection—remaining indoors (while preventing mosquitoes from entering) at dawn and dusk, wear light-colored clothing that covers arms and legs as well as trunk, use insect repellents on both skin and clothing (such as DEET, picaradin, or oil of lemon eucalyptus for skin and permethrin for clothes). If one becomes infected, generally, treatment is purely supportive: analgesia for the pain of neurologic diseases; rehydration for nausea, vomiting, or diarrhea; encephalitis may also require airway protection and seizure management.

Reported cases in the U.S. in 2005 exceeded those in 2004, and cases in 2006 exceeded 2005's totals. On August 19, 2006, the LA Times reported that the expected incidence rate of WNV was dropping as the local population becomes exposed to the virus. "In countries like Egypt and Uganda, where West Nile was first detected, people became fully immune to the virus by the time they reached adulthood", federal health officials said. However, just days later, the CDC said that WNV cases could reach a three-year high because hot temperatures had allowed a larger brood of mosquitoes. Although currently there is no West Nile Virus vaccine available for humans, many scientists are working on this issue, and there is hope that a vaccine will become available in the next few years.

Studies of phylogenetic lineages have determined that WNV emerged as a distinct virus around 1000 years ago. This initial virus developed into two distinct lineages, Lineage 1 and its multiple profiles is the source of the epidemic transmission in Africa and throughout the world. Lineage 2 was considered an Africa zoonose. However, in 2008, lineage 2, previously only seen in horses in sub-Saharan Africa and Madagascar, began to appear in horses in Europe, where the first known outbreak affected 18 animals in Hungary in 2008. Lineage 1 West Nile virus was detected in South Africa in 2010 in a mare and her aborted fetus; previously, only lineage 2 West Nile virus had been detected in horses and humans in South Africa.  A 2007 fatal case in a killer whale in Texas broadened the known host range of West Nile virus to include cetaceans.

WNV has been posited as one of the possible causes of Alexander the Great's early death based on reports of avian deaths before his illness period.[49]

WNV was first isolated from a feverish 37 year old woman at Omogo in the West Nile District of Uganda in 1937 during research on yellow fever virus.[50] A series of serosurveys in 1939 in central Africa found anti-WNV positive results ranging from 1.4% (Congo) to 46.4% (White Nile region, Sudan). It was subsequently identified in Egypt (1942) and India (1953), a 1950 serosurvey in Egypt found 90% of those over 40 years in age had WNV antibodies. The ecology was characterized in 1953 with studies in Egypt and Israel. The virus became recognized as a cause of severe human meningoencephalitis in elderly patients during an outbreak in Israel in 1957. The disease was first noted in horses in Egypt and France in the early 1960s and found to be widespread in southern Europe, southwest Asia and Australia.

The first appearance of WNV in the Western hemisphere was in 1999 with encephalitis reported in humans, dogs, cats, and horses, and the subsequent spread in the United States may be an important milestone in the evolving history of this virus. The American outbreak began in the New York City area (specifically, College Point, Queens) and was later seen in New Jersey and Connecticut; the virus is believed to have entered in an infected bird or mosquito, although there is no clear evidence. The US virus was very closely related to a lineage 1 strain found in Israel in 1998. Since the first North American cases in 1999, the virus has been reported throughout the United States, Canada, Mexico, the Caribbean and Central America. There have been human cases and equine cases, and many birds are infected. The Barbary Macaque, Macaca sylvanus, was the first non-human primate to contract WNV. Both the US and Israeli strains are marked by high mortality rates in infected avian populations; the presence of dead birds—especially corvidae—can be an early indicator of the arrival of the virus.

A high level of media coverage through 2001/2002 raised public awareness of WNV. This coverage was most likely the result of successive appearances of the virus in new areas, and had the unintended effect of increasing funding for research on this virus and related arthropod-borne viruses. Such research has expanded our understanding of viruses transmitted by mosquitoes.

Overwintering Mechanism
Vertical transmission of West Nile Virus from female Culex pipiens mosquitoes to their progeny has been demonstrated in the laboratory. It has not been suggested that vertically infected Culex could survive the winter to initiate a WNV amplification cycle the following spring. Culex mosquitoes spend the winter hibernating in protected structures such as root cellars, bank barns, caves, abandoned tunnels and other subterranean locations. The first overwintering adult mosquitoes to test positive for WNV were collected in New York, 2000. Since then, positive samples have been identified in New Jersey, 2003 and in Pennsylvania, 2003, 2004 and 2005.

Geographic Distribution
West Nile virus has been described in Africa, Europe, the Middle East, west and central Asia, Oceania (subtype Kunjin), and most recently, North America. Recent outbreaks of West Nile virus encephalitis in humans have occurred in Algeria (1994), Romania (1996 to 1997), the Czech Republic (1997), Congo (1998), Russia (1999), the United States (1999 to 2009), Canada (1999–2007), Israel (2000) and Greece (2010). Epizootics of disease in horses occurred in Morocco (1996), Italy (1998), the United States (1999 to 2001), and France (2000). In 2003, West Nile virus was found in horses in Mexico. In 2011, West Nile Virus was found in horses in Sardinia (Italy). In the US in 2008, West Nile virus was reported in animals in 47 states, D.C. and Puerto Rico. 45 states and D.C. reported human cases in 2008 with only Maine, Alaska and Hawaii having never had a human case. (Maine has had occasional animal cases.)

Recent outbreaks
United States: From 1999 through 2001, the CDC confirmed 149 West Nile virus infections, including 18 deaths. In 2002, a total of 4,156 cases were reported, including 284 fatalities. 13 cases in 2002 were contracted through blood transfusion. The cost of WNV-related health care in 2002 was estimated at $200 million. The first human West Nile disease in 2003 occurred in June and one West Nile-infected blood transfusion was also identified that month. In the 2003 outbreak, 9,862 cases and 264 deaths were reported by the CDC. At least 30% of those cases were considered severe involving meningitis or encephalitis. In 2004, there were only 2,539 reported cases and 100 deaths. In 2005, there was a slight increase in the number of cases, with 3,000 cases and 119 deaths reported. 2006 saw another increase, with 4,269 cases and 177 deaths. In 2007, the number of cases reported decreased to 3,623 and the number of deaths dropped to 124. In 2007, 1,227 cases of wnv neuroinvasion disease and 117 deaths occurred. In 2008, West Nile surveillance data reported to CDC, a total of 28 states have reported 236 cases of human WNV illness. A total of 137 cases for which such data were available occurred in males, median age patients was 48 years. Dates of illness onset ranged from January 17 to August 14: Two cases were fatal.

One human death occurred in 1999. In 2002, ten human deaths out of 416 confirmed and probable cases were reported by Canadian health officials. In 2003, 14 deaths and 1,494 confirmed and probable cases were reported. Cases were reported in 2003 in Nova Scotia, Quebec, Ontario, Manitoba, Saskatchewan, Alberta, British Columbia, and the Yukon. In 2004, only 26 cases were reported and two deaths; however, 2005 saw 239 cases and 12 deaths. By October 28, 2006, 127 cases and no deaths had been reported. One case was asymptomatic and only discovered through a blood donation. In 2007, 445 Manitobans had confirmed cases of WNV and two people died with a third unconfirmed but suspected. 17 people have either tested positive or are suspected of having the virus in Saskatchewan, and only one person has tested positive in Alberta. Saskatchewan has reported 826 cases of WNV plus three deaths. The spread of West Nile Virus infected mosquitoes to British Columbia for the first time was reported in 2009.

Israel: In the year 2000, the CDC found that there were 417 confirmed cases with 326 hospitalizations. 33 of these people died. The main clinical presentations were encephalitis (57.9%), febrile disease (24.4%), and meningitis (15.9%).

Romania: In 1996–1997 about 500 cases occurred in Romania with a fatality rate of nearly 10%. In 2010 there were 34 confirmed cases and 3 fatalities.

Greece: In the summer of 2010 several cases were reported in northern Greece. In total there were 261 diagnosed cases and 34 fatalities.

Surveillance Methods
West Nile virus can be sampled from the environment by the pooling of trapped mosquitoes, testing avian blood samples drawn from wild birds and dogs and sentinel monkeys, as well as testing brains of dead birds found by various animal control agencies and the public. Testing of the mosquito samples requires the use of RT-PCR to directly amplify and show the presence of virus in the submitted samples. When using the blood sera of wild bird and sentinel chickens, samples must be tested for the presence of WNV antibodies by use of immunohistochemistry (IHC) or Enzyme-Linked Immunosorbent Assay (ELISA). Dead birds, after necropsy, have their various tissues tested for virus by either RT-PCR or immunohistochemistry, where virus shows up as brown stained tissue because of a substrate-enzyme reaction.

West Nile control is achieved through mosquito control, by elimination of mosquito breeding sites, larviciding active breeding areas and encouraging personal use of mosquito repellents. The public is also encouraged to spend less time outdoors, wear long covering clothing, apply bug repellant that contains DEET and ensure that mosquitoes cannot enter buildings. Environmentalists have condemned attempts to control the transmitting mosquitoes by spraying pesticide, saying that the detrimental health effects of spraying outweigh the relatively few lives which may be saved, and that there are more environmentally friendly ways of controlling mosquitoes. They also question the effectiveness of insecticide spraying, as they believe mosquitoes that are resting or flying above the level of spraying will not be killed; the most common vector in the northeastern U.S., Culex pipiens, is a canopy feeder.

The first effective horse vaccine, West Nile-INNOVATOR was introduced by Fort Dodge Animal Health (Wyeth). Shortly thereafter, a second, one-annual-dose vaccine called Prevenile was introduced by Intervet/Schering-Plough Animal Health (Merck), followed by a DNA-based vaccine, called Recombitek (Merial). In 2009, a new killed virus vaccine was introduced by Boehringer-Ingelheim, a privately held pharmaceutical company, incorporating an equine origin WNV strain (E159), representative of the more recent WNV strains impacting horses.

Treatment Research
AMD3100, which had been proposed as an antiretroviral drug for HIV, has shown promise against West Nile encephalitis. Morpholino antisense oligos conjugated to cell penetrating peptides have been shown to partially protect mice from WNV disease. There have also been attempts to treat infections using ribavirin, intravenous immunoglobulin, or alpha interferon. GenoMed, a U.S. biotech company, has found that blocking angiotensin II can treat the "cytokine storm" of West Nile virus encephalitis as well as other viruses.

In 2007 the World Community Grid launched the Discovering Dengue Drugs – Together project. This uses a distributed network of volunteers' computers via the Berkeley Open Infrastructure for Network Computing (BOINC) to perform computer simulations of interacting molecules. Thousands of small molecules are screened for potential anti-viral properties with respect to West Nile and related viruses (Wikipedia, 2012).